The "mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization] ...

Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

The highlight of the New Jersey-based company’s move into Australia is that it can provide next-day shipping for high-demand products, such as off-the-shelf mRNA, growth factors ... Johnson on CAR-T ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Following the game-changing success of Spinraza, a molecular-based therapy that was crucial in the treatment of ... is the recipe for success". He added that mRNA vaccine technology, made famous ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Good afternoon, ladies and gentlemen, and welcome everyone to the Maravai Life Sciences third-quarter 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to ...

The strategy, called gene drive, pushes a genetic variant into a population that then retools HSV DNA, which then targets latent, infected neurons. If successful, it would be the second gene therapy ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Maravai Lifesciences Holdings, Inc. ( (MRVI) ) has released its Q3 earnings. Here is a breakdown of the information Maravai Lifesciences ...